Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1

INTRODUCTION: To improve the standard treatment paradigm for glioblastoma (GBM), efforts have been made to explore the efficacy of epigenetic agents as chemosensitizers. Recent data suggest possible synergy between decitabine (DAC), a DNA hypomethylating agent, and temozolomide (TMZ) in GBM, but the...

Descripción completa

Detalles Bibliográficos
Autores principales: Gallitto, Matthew, Cheng He, Rossana, Inocencio, Julio F., Wang, Huaien, Zhang, Yizhou, Deikus, Gintaras, Wasserman, Isaac, Strahl, Maya, Smith, Melissa, Sebra, Robert, Yong, Raymund L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Laboratory Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256087/
https://www.ncbi.nlm.nih.gov/pubmed/32193690
http://dx.doi.org/10.1007/s11060-020-03461-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256087/
https://www.ncbi.nlm.nih.gov/pubmed/32193690
http://dx.doi.org/10.1007/s11060-020-03461-4

Ejemplares similares